Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $38.5 million.

  • Beta Bionics' Cash & Equivalents rose 12015.33% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.5 million, marking a year-over-year increase of 12015.33%. This contributed to the annual value of $30.4 million for FY2024, which is 1455.24% up from last year.
  • According to the latest figures from Q3 2025, Beta Bionics' Cash & Equivalents is $38.5 million, which was up 12015.33% from $35.1 million recorded in Q2 2025.
  • Over the past 5 years, Beta Bionics' Cash & Equivalents peaked at $42.5 million during Q1 2025, and registered a low of $13.0 million during Q2 2024.
  • For the 3-year period, Beta Bionics' Cash & Equivalents averaged around $28.2 million, with its median value being $28.5 million (2023).
  • Per our database at Business Quant, Beta Bionics' Cash & Equivalents surged by 1455.24% in 2024 and then soared by 16920.72% in 2025.
  • Quarter analysis of 3 years shows Beta Bionics' Cash & Equivalents stood at $26.6 million in 2023, then increased by 14.55% to $30.4 million in 2024, then rose by 26.46% to $38.5 million in 2025.
  • Its last three reported values are $38.5 million in Q3 2025, $35.1 million for Q2 2025, and $42.5 million during Q1 2025.